Ovarian cancer, a deadly gynecologic malignancy, has seen a significant shift in its treatment paradigm with the introduction ...

Table 1. Poly-(ADP-ribose) polymerase inhibitors in clinical studies. PARP inhibitor Number of completed or ongoing studies Type of studies completed or ongoing Specific tissue cancers that were ...

The first wave of PARP inhibitors has improved outcomes in people with a variety of solid tumors. However, Idience has identified opportunities to improve the efficacy of existing drugs and ...

Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor that works by preventing this protein in cancer cells from repairing damaged DNA in patients with BRCA mutations. This causes cancer ...

MOMA Therapeutics on Wednesday said it added the next-generation PARP1 inhibitor MOMA-989 to its pipeline of drug candidates and anticipates filing an investigational new drug application by year end ...

This study is looking at tissue and blood samples to work out who benefits most from having a PARP inhibitor. The study is for women who have: ovarian cancer primary peritoneal cancer fallopian tube ...

Haisco Pharmaceutical Group Co. Ltd. has disclosed quinazolinone derivatives acting as poly(ADP-ribose) polymerase 14 (PARP-14; ARTD8) inhibitors reported to be useful for the treatment of cancer, ...

The digital meeting will capitalize on the therapeutic application of PARP inhibitors by finding optimal treatment combinations and expanding its use in cancer indications, as well as exploring ...

In the United States, The NeuroMedical Center Clinic and UC San Diego Moores Cancer Center have been ... improve the efficacy of radiotherapy. PARP inhibition has a strong rationale, and niraparib ...

Personalized Medicine. 2015;12(2):139-154. Compared to AstraZeneca, the other pharmaceutical companies have fewer Phase III trials running for their compounds. However, the approaches within these ...